TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01234285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
Study: NCT01440764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study: NCT04435743

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles.

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles.
Study: NCT04151095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTL Exercise Training
Description: Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
Study: NCT01545609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Text messages to cell phone with education messages about the specific birth control they are using
Study: NCT00126789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal Matrix Patch ZR-02-01
Description: ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
Study: NCT03090464

Intervention type: OTHER
Intervention: Use of digital disease management tool
Description: The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
Study: NCT00928356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid CABG/PCI
Description: Same sitting hybrid, robotic CABG/PCI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Off Pump CABG
Description: Standard of Care Off Pump CABG
Study: NCT03771599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
Study: NCT04435743

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles.
Study: NCT03849105

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4-L-[131I]iodo-phenylalanine (131I-IPA)
Description: Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4-L-[131I]iodo-phenylalanine (131I-IPA)
Description: Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4-L-[131I]iodo-phenylalanine (131I-IPA)
Description: Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4-L-[131I]iodo-phenylalanine (131I-IPA)
Description: Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy
Study: NCT00154349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study: NCT03910647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: effect of this drug on renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: effect of this drug on renal function
Study: NCT03569943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot Based Transtympanic drain placement
Description: Placement of a transtympanic drain with a robot based device assistance called RobOtol
Study: NCT00659282

Intervention type: DRUG
Intervention: biphasic insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
Study: NCT00256126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen
Description: Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen
Description: Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
Study: NCT01864824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methyl donor
Description: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
Study: NCT01394380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: artificially sweetened sodas
Description: subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
Study: NCT04473001

Intervention type: OTHER
Intervention: Continuous vital signs and glucose monitoring
Description: The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~* Glucose measurements (quasi-continuous, every 5 minutes)~* Heart rate~* Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Respiration rate~* Oxygen saturation of arterial hemoglobin (%SpO2)~* Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~* Blood pressure (quasi-continuous; every 30-60 minutes)~* Skin temperature~* Electrodermal activity~* Ambulatory activity (accelerometry)
Study: NCT00387088

Intervention type: DEVICE
Group type: OTHER
Intervention: Respimat

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium
Study: NCT04034134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: 50 mg twice-daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: 150 mg quaque die (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: 200 mg quaque die (QD)
Study: NCT04097990

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
Study: NCT02280993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHAP
Description: DHAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell Transplantation
Description: Autologous Peripheral Blood Stem Cell Transplantation
Study: NCT02054637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Study: NCT01500317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol
Description: Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo three times per day (tid) for 48 hours.
Study: NCT00827229

Intervention type: DEVICE
Group type: OTHER
Intervention: Labor Monitor
Study: NCT00102661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
Study: NCT03263403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ingovax ACWY
Description: The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
Study: NCT01234285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin
Description: intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: 5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
Study: NCT03263403

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadri Meningo
Description: Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo \[Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined\] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
Study: NCT02015403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care + NAC (N -ACETYLCYSTEINE)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (in control arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care (in control arm)
Study: NCT06250764

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical periodontal measuremenets
Description: The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical periodontal measuremenets
Description: The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical periodontal measuremenets
Description: The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical periodontal measuremenets
Description: The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G
Study: NCT01864824

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01140893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03584360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone-Calcipotriene Topical
Description: Comparison between betamethasone-calcipotriol and placebo
Study: NCT04438252

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICDAS II
Description: Index for caries detection
Study: NCT06250764

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA test from gingival crevicular fluid (GCF)
Description: GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA test from gingival crevicular fluid (GCF)
Description: GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA test from gingival crevicular fluid (GCF)
Description: GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA test from gingival crevicular fluid (GCF)
Description: GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively
Study: NCT01874392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational inhaled insulin (Technosphere)
Description: by MannKind Corp. IND 61,729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (AP) device (APS©)
Description: Device includes:~* OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~* Dexcom® G4® CGM System (CGM) from Dexcom® Corp~* Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)
Study: NCT03692403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide 360 µg
Description: Vaginal ring containing quinagolide 360 µg for daily releases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide 720 µg
Description: Vaginal ring containing quinagolide 720 µg for daily releases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide 1080 µg
Description: Vaginal ring containing quinagolide 1080 µg for daily releases

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02030132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback compared to 75th percentile

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback compared to 75th percentile
Study: NCT03584360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone-Calcipotriene Topical
Description: Comparison between betamethasone-calcipotriol and betamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone-Calcipotriene Topical
Description: Comparison between betamethasone-calcipotriol and propionate de clobetasol
Study: NCT00726986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
Study: NCT02687633

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.